EMBL Cancer Genomics 2025

Distinguish 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) together with all 4 canonical bases to measure multiple modes of biology from a single 5ng DNA sample, in a single experiment, with high accuracy. Identify novel multimodal biomarkers to gain transformative insights into current and future states of disease.
11 November 2025
to 14 November 2025
EMBL Heidelberg
, Heidelberg

About the event

This conference will provide an opportunity to learn about and keep up to date with the progressing area of cancer genomics.

It will cover presentations from cancer genome projects, the areas of cancer functional genomics, systems biology, cancer immunogenomics and epigenomics, and the translation and clinical impact of scientific results.

The meeting will bring together leading scientists and academic clinicians from across these areas for a unique opportunity to interact and stimulate further integration of these efforts.

  • Clonal evolution and tumorigenesis
  • Early detection and molecular stratification
  • Structural variation and mutational signatures
  • Cancer microenvironment and immunogenomics
  • Genomics underpinnings of cancer disparities

Find the venue

One sample. One workflow. One solution.

Here are the relevant biomodal resources for information. Find poster presentation information, case studies, interviews, and more.

Cancer research

Discover how alterations in DNA methylation play a crucial role in cancer research via gene expression changes and mutation occurrence. Learn more.

Discover more

Related resources

Attending from biomodal

Dirk Bartels

Dirk Bartels, PhD

Business Development Manager
Sascha Seidel

Sascha Seidel, PhD

Field Advisory Scientist – DACH

Register now

EMBL Cancer 2025

Stay up to date

Explore recent biomodal news and the events that we’ll be attending in the near future.